Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908015 | 0.86 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1TSHRHPGD | |
| SCHEMBL23884283 | 0.82 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1TSHRHPGD | |
| SCHEMBL23884202 | 0.82 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1TSHRHPGD | |
| SCHEMBL23907997 | 0.81 | ALDH1A1 (0.43) | TP53KMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL23908018 | 0.79 | ATM (0.45) | KMT2AMEN1ALDH1A1TSHRHPGD | |
| SCHEMBL23907976 | 0.79 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1TSHRHPGD | |
| SCHEMBL23908001 | 0.79 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1TSHRHPGD | |
| SCHEMBL23907975 | 0.79 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1TSHRHPGD | |
| SCHEMBL23908012 | 0.79 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1TSHRHPGD | |
| SCHEMBL23908021 | 0.79 | PTPRC (0.45) | KMT2AMEN1ALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932626-B2 | 2-pyrimidone analogs as potent antiviral agents against Alphaviruses | SOUTHERN RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230120566-A1 | Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | OREGON HEALTH AND SCIENCE UNIVERSITY | 2023-04-20 | — | — | US | disclosed |
| CN-115916175-A | Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses | 南方研究院 | 2023-04-04 | — | — | CN | disclosed |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | SOUTHERN RESEARCH INSTITUTE (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | SOUTHERN RES INST (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | TP53 3322/4885CNR2 4380/4885KMT2A 2117/4885 |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | EIF2AK2, ZC3HAV1, MAVS | TP53 3322/4885CNR2 4380/4885KMT2A 2117/4885 |
| US-11932626-B2 | 2-pyrimidone analogs as potent antiviral agents against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | TP53 3322/4885CNR2 4380/4885KMT2A 2117/4885 |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | TP53 3322/4885CNR2 4380/4885KMT2A 2117/4885 |
| US-20230120566-A1 | Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | TP53 3894/4885CNR2 4247/4885KMT2A 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.